BPC-157
Widely discussed for tissue repair and gut healing, but NOT FDA-approved. Human evidence is extremely limited despite popular claims.
This peptide is not FDA-approved for any indication. Human use outside of clinical trials is not recommended.
The basics
- Generic Name
- BPC-157 (Body Protection Compound-157)
- Brand Names
- None (not an approved product)
- Regulatory Status
- Early Research
- Therapeutic Areas
- Musculoskeletal, Gastrointestinal
Wellness Goals
Important: This peptide is not yet FDA-approved
BPC-157 has not been approved by the FDA for any use in humans. That means it hasn't gone through the rigorous testing process that confirms a drug is safe and effective. Products sold online have not been evaluated by any regulatory body.
Heads up: The FDA has flagged some safety concerns with this one. That doesn't mean it's definitely dangerous, but it means we don't know enough yet.
What it does
BPC-157 (BPC-157 (Body Protection Compound-157)) is a synthetic peptide that researchers are studying, but it's not yet FDA-approved for any human use. A pentadecapeptide fragment derived from human gastric juice protein. Proposed mechanisms include modulation of nitric oxide pathways, growth factor expression, and angiogenesis, but human evidence is extremely limited.
The research is still early. Most studies so far are in animals or lab settings, so we don't know for sure how well this translates to real-world results in people.
How it's taken
Subcutaneous injection
Oral capsule
Nasal spray
How people access it
BPC-157 is currently Category 1 compounding-eligible after HHS restored access in February 2026. A doctor writes a prescription and sends it to a licensed compounding pharmacy (503A or 503B). Not available at regular retail pharmacies. Typical cost: $150-350/month through a compounding pharmacy.
Regulatory Status
Not FDA-approved. Listed by FDA as a substance that may present significant safety risks for compounding.
FDA Safety-Risk Designation
This substance appears on the FDA's list of substances that may present significant safety risks when used in compounding. This designation indicates that the FDA has identified concerns about the safety of this substance that have not been adequately addressed through clinical testing.
Any use in humans outside of an FDA-authorized clinical trial would require an Investigational New Drug (IND) application. Products marketed as “for research use only” are not legally intended for human administration.
What the Evidence Shows
The evidence base for BPC-157 consists primarily of preclinical studies (animal models and in vitro experiments). There are no completed, large-scale, peer-reviewed clinical trials establishing safety or efficacy in humans. The gap between promising animal data and proven human benefit is substantial — many compounds that show effects in animal studies fail to demonstrate safety or efficacy in human trials.
Marketing claims made by online sellers and “peptide clinics” frequently overstate the evidence and omit critical information about risks and unknowns.
Other options to consider
Depending on what you're hoping to achieve, there may be FDA-approved treatments that have been rigorously tested and proven to work. Discuss evidence-based options with your own healthcare provider to find what fits your specific goals.
Browse our full peptide directory to see FDA-approved options that might work for you.
Common Questions
No. BPC-157 is not FDA-approved for any use in humans. It has no approved New Drug Application (NDA) or Biologics License Application (BLA). The FDA has listed BPC-157 as a substance that may present significant safety risks when used in compounding, and it cannot be legally marketed as a drug in the United States.
There is no adequate evidence to establish the safety of BPC-157 injections in humans. Nearly all published studies are in animal models. Products sold online as BPC-157 are not manufactured under FDA-regulated conditions and may contain impurities, incorrect dosages, or contaminants. Injecting unregulated substances carries serious risks including infection, adverse reactions, and unknown long-term effects.
There are currently no completed, large-scale clinical trials of BPC-157 in humans. Most published research consists of animal studies. Some early-phase or investigator-initiated studies may appear in trial registries, but no results have led to regulatory approval. The lack of human clinical data remains a major gap in the evidence base.
Curious about what IS approved?
Check out FDA-approved peptides that address similar goals — with established safety profiles and real clinical evidence.
See Approved Options